非小细胞肺癌术后辅助化疗研究进展

Research progress of post-operative adjuvant chemotherapy in non-small cell lung cancer

完全切除的非小细胞肺癌（NSCLC）是否需要术后辅助化疗是多年来肺癌治疗领域的研究热点，随着各种新药及新的联合化疗方案的出现，几项大型随机临床试验论证了含铂类药物术后辅助化疗可以延长患者生存期，从而奠定了肺癌术后辅助化疗的地位，但目前术后辅助化疗的预后和其疗效预测仍有很多未知因素。

The post-operative adjuvant chemotherapy for non-small cell lung cancer（NSCLC） has been a highlight around the world. Along with the appearance of each kind of new drugs and new combined therapeu- tic regimen, several randomized clinical trials have demonstrated a clear survival advantage for patients treated with platin-based adjuvant therapy. Nevertheless, the prognosis and efficiency prediction of postoperative adjuvant chemotherapy is still uncertain at present.